Gilead Sciences

Gilead Sciences Stock Trades Flat; Neutral Rating by Zacks Research with $89 Price Target

Judy Costner 12 October 2024
Gilead Sciences Stock Trades Flat; Neutral Rating by Zacks Research with $89 Price Target

Gilead Sciences Inc.

Dr Reddy's Share Price in Focus after Agreement with Gilead Sciences to Produce Lenacapavir

Akash Verma 3 October 2024
Dr Reddy's Share Price in Focus after Agreement with Gilead Sciences to Produce Lenacapavir

Dr. Reddy’s Laboratories has entered into a significant collaboration with Gilead Sciences to manufacture and commercialize the HIV drug Lenacapavir in India and 120 other countries.

Gilead Sciences CEO aims at widely available Coronavirus Treatment

Piyush Diwan 2 May 2020
Gilead Sciences CEO aims at widely available Coronavirus Treatment

Gilead Sciences CEO Daniel O’Day said on Friday that the company is focused on experimental coronavirus drug that is affordable and widely accessible.